DRUGDOCS®
@drugdocs.bsky.social
DRUGDOCS® provides health professionals with current best evidence on the drugs they prescribe with direct access to publications.
Ottawa, Canada | https://drugdocs.com/
Ottawa, Canada | https://drugdocs.com/
The FDA has approved Enflonsia® (clesrovimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season.
💊 Find the clinical evidence for Enflonsia at DRUGDOCS® here: drugdocs.com/drug/Enflonsia
💊 Find the clinical evidence for Enflonsia at DRUGDOCS® here: drugdocs.com/drug/Enflonsia
February 11, 2026 at 11:11 PM
The FDA has approved Enflonsia® (clesrovimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season.
💊 Find the clinical evidence for Enflonsia at DRUGDOCS® here: drugdocs.com/drug/Enflonsia
💊 Find the clinical evidence for Enflonsia at DRUGDOCS® here: drugdocs.com/drug/Enflonsia
📊 Top 3 drugs searched on DRUGDOCS® in January:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Erleada® – Prostate cancer therapy
3️⃣ Avastin® – Anti-VEGF oncology mainstay
Explore the clinical evidence: drugdocs.com
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Erleada® – Prostate cancer therapy
3️⃣ Avastin® – Anti-VEGF oncology mainstay
Explore the clinical evidence: drugdocs.com
February 9, 2026 at 4:47 PM
📊 Top 3 drugs searched on DRUGDOCS® in January:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Erleada® – Prostate cancer therapy
3️⃣ Avastin® – Anti-VEGF oncology mainstay
Explore the clinical evidence: drugdocs.com
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Erleada® – Prostate cancer therapy
3️⃣ Avastin® – Anti-VEGF oncology mainstay
Explore the clinical evidence: drugdocs.com
Vanrafia® (atrasentan) received accelerated FDA approval for reducing proteinuria in adults with primary IgA nephropathy. Phase 3 trial data showed a 36.1% reduction vs placebo, supporting its role as a new treatment option.
💊 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Vanrafia
💊 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Vanrafia
February 5, 2026 at 3:43 PM
Vanrafia® (atrasentan) received accelerated FDA approval for reducing proteinuria in adults with primary IgA nephropathy. Phase 3 trial data showed a 36.1% reduction vs placebo, supporting its role as a new treatment option.
💊 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Vanrafia
💊 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Vanrafia
The FDA has approved Journavx® (suzetrigine), a first-in-class non-opioid oral analgesic for moderate to severe acute pain in adults. The drug demonstrated significant pain reduction in clinical trials.
💊Find the clinical evidence for Journavx on DRUGDOCS® here: drugdocs.com/drug/Journavx
💊Find the clinical evidence for Journavx on DRUGDOCS® here: drugdocs.com/drug/Journavx
February 3, 2026 at 4:23 PM
The FDA has approved Journavx® (suzetrigine), a first-in-class non-opioid oral analgesic for moderate to severe acute pain in adults. The drug demonstrated significant pain reduction in clinical trials.
💊Find the clinical evidence for Journavx on DRUGDOCS® here: drugdocs.com/drug/Journavx
💊Find the clinical evidence for Journavx on DRUGDOCS® here: drugdocs.com/drug/Journavx
The FDA has approved Grafapex® (treosulfan) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adults & children (≥1 yr) with acute myeloid leukemia or myelodysplastic syndrome.
💊Find the clinical evidence for Grafapex® at drugdocs.com/drug/Grafapex
💊Find the clinical evidence for Grafapex® at drugdocs.com/drug/Grafapex
February 3, 2026 at 4:21 PM
The FDA has approved Grafapex® (treosulfan) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adults & children (≥1 yr) with acute myeloid leukemia or myelodysplastic syndrome.
💊Find the clinical evidence for Grafapex® at drugdocs.com/drug/Grafapex
💊Find the clinical evidence for Grafapex® at drugdocs.com/drug/Grafapex
The #1 most searched drug on DRUGDOCS® in 2025 is OZEMPIC® (semaglutide), a leading GLP-1 receptor agonist for adults with type 2 diabetes — lowering blood sugar and reducing the risk of heart attack, stroke, and progression of kidney disease
💊 Find the clinical evidence: drugdocs.com/drug/Ozempic
💊 Find the clinical evidence: drugdocs.com/drug/Ozempic
January 27, 2026 at 3:01 PM
The #1 most searched drug on DRUGDOCS® in 2025 is OZEMPIC® (semaglutide), a leading GLP-1 receptor agonist for adults with type 2 diabetes — lowering blood sugar and reducing the risk of heart attack, stroke, and progression of kidney disease
💊 Find the clinical evidence: drugdocs.com/drug/Ozempic
💊 Find the clinical evidence: drugdocs.com/drug/Ozempic
46 New Drugs. One Year. A Growing Evidence Base.
In 2025, the FDA approved 46 novel drugs. While annual totals fluctuate, the long-term trend shows continued momentum in drug innovation and clinical evidence.
DRUGDOCS® helps clinicians stay current with the evidence behind every approval.
In 2025, the FDA approved 46 novel drugs. While annual totals fluctuate, the long-term trend shows continued momentum in drug innovation and clinical evidence.
DRUGDOCS® helps clinicians stay current with the evidence behind every approval.
January 22, 2026 at 2:31 PM
46 New Drugs. One Year. A Growing Evidence Base.
In 2025, the FDA approved 46 novel drugs. While annual totals fluctuate, the long-term trend shows continued momentum in drug innovation and clinical evidence.
DRUGDOCS® helps clinicians stay current with the evidence behind every approval.
In 2025, the FDA approved 46 novel drugs. While annual totals fluctuate, the long-term trend shows continued momentum in drug innovation and clinical evidence.
DRUGDOCS® helps clinicians stay current with the evidence behind every approval.
Counting down the Top 3 Drug Searches on DRUGDOCS in 2025.
#2: AVASTIN® (bevacizumab), remains a key anti-VEGF agent in oncology, used in combination across CRC, NSCLC, ovarian cancer and more, plus potential new combinations with immunotherapy.
💊 Clinical evidence: drugdocs.com/drug/Avastin
#2: AVASTIN® (bevacizumab), remains a key anti-VEGF agent in oncology, used in combination across CRC, NSCLC, ovarian cancer and more, plus potential new combinations with immunotherapy.
💊 Clinical evidence: drugdocs.com/drug/Avastin
January 21, 2026 at 2:59 PM
Counting down the Top 3 Drug Searches on DRUGDOCS in 2025.
#2: AVASTIN® (bevacizumab), remains a key anti-VEGF agent in oncology, used in combination across CRC, NSCLC, ovarian cancer and more, plus potential new combinations with immunotherapy.
💊 Clinical evidence: drugdocs.com/drug/Avastin
#2: AVASTIN® (bevacizumab), remains a key anti-VEGF agent in oncology, used in combination across CRC, NSCLC, ovarian cancer and more, plus potential new combinations with immunotherapy.
💊 Clinical evidence: drugdocs.com/drug/Avastin
The UK’s Medicines and Healthcare products Regulatory Agency has authorised GSK’s Nucala (mepolizumab) for adults with uncontrolled eosinophilic COPD on triple therapy, following positive phase 3 data. NICE review is next.
Find the clinical evidence for Nucala at: drugdocs.com/search/nucala
Find the clinical evidence for Nucala at: drugdocs.com/search/nucala
MHRA approves Nucala for eosinophilic COPD in adults on triple therapy - PharmaTimes
New biologic option shown to reduce exacerbations and extend time to first flare
pharmatimes.com
January 14, 2026 at 10:14 PM
The UK’s Medicines and Healthcare products Regulatory Agency has authorised GSK’s Nucala (mepolizumab) for adults with uncontrolled eosinophilic COPD on triple therapy, following positive phase 3 data. NICE review is next.
Find the clinical evidence for Nucala at: drugdocs.com/search/nucala
Find the clinical evidence for Nucala at: drugdocs.com/search/nucala
Counting down the Top 3 Drug Searches on @drugdocs.bsky.social in 2025.
#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.
💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS
#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.
💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS
January 12, 2026 at 7:13 PM
Counting down the Top 3 Drug Searches on @drugdocs.bsky.social in 2025.
#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.
💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS
#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.
💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS
FDA approves Omisirge, the first cellular therapy for severe aplastic anemia.
💊Find the clinical evidence for aplastic anemia treatments at DRUGDOCS: drugdocs.com/search/sever...
📄Read more here: www.fda.gov/news-events/...
💊Find the clinical evidence for aplastic anemia treatments at DRUGDOCS: drugdocs.com/search/sever...
📄Read more here: www.fda.gov/news-events/...
January 2, 2026 at 5:46 PM
FDA approves Omisirge, the first cellular therapy for severe aplastic anemia.
💊Find the clinical evidence for aplastic anemia treatments at DRUGDOCS: drugdocs.com/search/sever...
📄Read more here: www.fda.gov/news-events/...
💊Find the clinical evidence for aplastic anemia treatments at DRUGDOCS: drugdocs.com/search/sever...
📄Read more here: www.fda.gov/news-events/...
Happy New Year! 🎉 Here’s to a 2026 filled with new beginnings, big ideas, and bright moments. Wishing you all the best from everyone at DRUGDOCS! ✨
#HappyNewYear #Welcome2026
#HappyNewYear #Welcome2026
January 1, 2026 at 4:00 PM
Happy New Year! 🎉 Here’s to a 2026 filled with new beginnings, big ideas, and bright moments. Wishing you all the best from everyone at DRUGDOCS! ✨
#HappyNewYear #Welcome2026
#HappyNewYear #Welcome2026
EC approves Gobivaz, the first biosimilar to Simponi (golimumab) in the EEA. Developed by Alvotech and commercialised by Advanz Pharma, it’s approved for multiple immune-mediated diseases in adults and children.
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
Gobivaz approved across Europe as first Simponi biosimilar - PharmaTimes
Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases
pharmatimes.com
December 30, 2025 at 10:15 PM
EC approves Gobivaz, the first biosimilar to Simponi (golimumab) in the EEA. Developed by Alvotech and commercialised by Advanz Pharma, it’s approved for multiple immune-mediated diseases in adults and children.
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
💊 Find clinical evidence for Simponi at: drugdocs.com/drug/Simponi
📰 Read more here:
Season’s greetings to all who are celebrating Christmas!🎄🎁 Wishing you a joyful, cozy, and relaxing holiday season.✨🎅
#MerryChristmas #HappyHolidays
#MerryChristmas #HappyHolidays
December 25, 2025 at 9:44 PM
Season’s greetings to all who are celebrating Christmas!🎄🎁 Wishing you a joyful, cozy, and relaxing holiday season.✨🎅
#MerryChristmas #HappyHolidays
#MerryChristmas #HappyHolidays
Wishing you peace, joy, and celebration this holiday season! ✨
We’re grateful for your support and collaboration this year. Happy Holidays from our team to yours! 🎉
#SeasonsGreetings
We’re grateful for your support and collaboration this year. Happy Holidays from our team to yours! 🎉
#SeasonsGreetings
December 24, 2025 at 5:14 PM
Wishing you peace, joy, and celebration this holiday season! ✨
We’re grateful for your support and collaboration this year. Happy Holidays from our team to yours! 🎉
#SeasonsGreetings
We’re grateful for your support and collaboration this year. Happy Holidays from our team to yours! 🎉
#SeasonsGreetings
As this year comes to an end, we are counting down the top 3 drugs most searched on DRUGDOCS® in 2025! Stay tuned for the reveal in January!
#EvidenceBasedMedicine #DRUGDOCS
#EvidenceBasedMedicine #DRUGDOCS
December 22, 2025 at 10:03 PM
As this year comes to an end, we are counting down the top 3 drugs most searched on DRUGDOCS® in 2025! Stay tuned for the reveal in January!
#EvidenceBasedMedicine #DRUGDOCS
#EvidenceBasedMedicine #DRUGDOCS
Ascletis’ oral GLP-1 ASC30 achieved up to 7.7% weight loss at 13 weeks with mild GI events and lower vomiting rates than those publicly reported for orforglipron. A new entrant in the growing oral obesity treatment field.
💊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/search/GLP-1
💊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/search/GLP-1
December 17, 2025 at 5:55 PM
Ascletis’ oral GLP-1 ASC30 achieved up to 7.7% weight loss at 13 weeks with mild GI events and lower vomiting rates than those publicly reported for orforglipron. A new entrant in the growing oral obesity treatment field.
💊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/search/GLP-1
💊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/search/GLP-1
Wishing a joyful and meaningful Hanukkah to all who observe. May this Festival of Lights bring warmth, reflection, and peace to you and your loved ones. ✨
#Hanukkah #FestivalOfLights
#Hanukkah #FestivalOfLights
December 15, 2025 at 8:19 PM
Wishing a joyful and meaningful Hanukkah to all who observe. May this Festival of Lights bring warmth, reflection, and peace to you and your loved ones. ✨
#Hanukkah #FestivalOfLights
#Hanukkah #FestivalOfLights
Top 3 drugs searched on DRUGDOCS® in November:
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
December 12, 2025 at 3:51 PM
Top 3 drugs searched on DRUGDOCS® in November:
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
December 8, 2025 at 4:23 PM
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
December 5, 2025 at 10:10 PM
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
It’s #CrohnsAndColitisAwarenessWeek (Dec 1–7).
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
December 3, 2025 at 2:42 PM
It’s #CrohnsAndColitisAwarenessWeek (Dec 1–7).
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Let’s raise awareness for the 10M+ people globally living with IBD.
💜 Understand the impact
💡 Share resources
🤝 Support the community
More info: crohnscolitisfoundation.org
#IBDAwareness #CCAwarenessWeek
@crohnscolitisfdn.bsky.social
Dec 1 is #WorldAIDSDay, a moment to honour lives lost, support those living with HIV, and call for action to end AIDS.
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
December 1, 2025 at 7:37 PM
Dec 1 is #WorldAIDSDay, a moment to honour lives lost, support those living with HIV, and call for action to end AIDS.
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
This year’s theme, Overcoming Disruption, Transforming the AIDS Response, highlights the need for global solidarity, sustained investment, and action.
#EndAIDS #HIVAwareness
Wishing you and your loved ones a restful, joyful, and abundant holiday season. 🦃🍂
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
November 28, 2025 at 1:55 AM
Wishing you and your loved ones a restful, joyful, and abundant holiday season. 🦃🍂
Happy Thanksgiving from all of us at @drugdocs.bsky.social!
Happy Thanksgiving from all of us at @drugdocs.bsky.social!